11 results about "Half-life" patented technology

The recombinant human interferon modified by polyethylene glycol is characterized by that on the recombinant human interferon one or two or more than two polyethylene glycol chains can be connected, said recombinant human interferon can be interferon alpha 2b, and the average degree of polymerization of said polyethylene glycol chain is 45-230. Said invented recombinant human interferon has the physiological activity of the interferon, and its stability is superior to that of interferon, its plasma clearance is low, the half-life period in vivo is long, it can be used for preparing the medicines for resisting virus and resisting cancer. Said invention also discloses its preparation method.

The invention relates to a preparation of and compound injection formed by ª‰-lactam antibiotics and it and its application, which belongs to chemical chemical tragacanth . Make intosodium salt and kali salt, combined with ª‰-lactam antibiotics thy are then changes into powder injection; which can intravenous injection or intravenous drip with ª‰-lactam antibiotics at the sametime. It can remarktably increase the square below the curve, prolong half life of blood elimination (t1/2ª‰) of antibiotics, and the period of medicine density of ª‰-lactam antibiotics in blood surpassing that of the corresponding germ MIC; it can also reduce abuse of antibiotics, avoid generation and development of bacterial strain tolerant to medicine, has good safety and curative effect, stable quality and convenient use.

The invention discloses an environment-friendly composite alkaline foam cleaning agent and a preparation method thereof. The environment-friendly composite alkaline foam cleaning agent is prepared from water, sodium hydroxide, a foaming agent, a foam stabilizing agent, a dispersing agent, a chelating agent and alkylolamide. The foam cleaning agent has the advantages of being high in permeability,efficient, clean, easy to flush and the like, can form a large amount of rich and delicate foam in the use process, has long half-life and wall hanging time, can be attached to the surface of equipment for 25 min or longer, can rapidly infiltrate dirt to soften, loosen and emulsify the dirt, reduces adhesion of the dirt, can completely remove the dirt of the equipment and has lower cost.

The invention belongs to the field of biological medicine, and relates to a long-acting HIV fusion inhibitor for treating acquired immune deficiency syndrome and application thereof. The long-acting HIV fusion inhibitor comprises a polypeptide part for inhibiting HIV membrane fusion and a part capable of being specifically combined with human immune globulin Fc, it is proved through experiments that the half-life period of the long-acting HIV fusion inhibitor in a rhesus monkey is about 11 times that of the HIV fusion inhibitor T20 which is first approved for marketing and has excellent antiviral activity to HIV-1IIIB and HIV-1Bal, the IC50 values are about 5.9 nM and 2.57 nM respectively, the antiviral activity is about 3 times that of T20, and the long-acting HIV fusion inhibitor has low toxicity to cells. The long-acting HIV fusion inhibitor IBP-CP24 polypeptide can be used for preparing a drug for resisting human immunodeficiency viruses for a long time and providing a new strategy for prolonging the half-life period of protein and polypeptide drugs in the body.

The invention discloses an ephedra, almond gypsum and licorice granule pill. The ephedra, almond gypsum and licorice granule pill comprises a base pill (1) as the core, a medicine layer (2) obtained by mixing ephedra, almond gypsum and licorice granules, monoglyceride, hydroxy propyl methyl cellulose and acrylic resin, a coating layer (3) and a color coating layer (4), wherein the base pill (1) is coated with the medicine layer (2); the polymer slow-release coating layer (3) and the color coating layer (4) are sequentially coated layer by layer outwards. The invention solves the problems that ephedra, almond gypsum and licorice granules are short in half-life period and more frequent in administration, and makes up the shortfall in the prior art.

The invention discloses an application of amomum tsao-ko essential oil, an application of the amomum tsao-ko essential oil in preparing drugs for the treatment or prevention of brain dysfunction and other disorder disease and an application of the amomum tsao-ko essential oil in preparing health products for improving brain function and disorder diseases. For the first time, the amomum tsao-ko essential oil is found to have a new use in medicine or large health products that show activity in brain function and disorder diseases of experimental animals, and for the first time, the amommum tsao-ko essential oil or arbitrary components containing the amommum tsao-ko essential oil can improve brain function such as Alzheimer's disease, depression and anxiety in animal body models and the symptoms of disordered animals; compared with traditional medicine for treating the brain function and disorders, the amomum tsao-ko essential oil or the arbitrary components thereof has the mechanism of inhibiting the action of multi-molecular synergy of the cholinesterase and regulating the synergistic action of multiple molecules, such as neurotransmitters, on multiple targets, and is good in drug substitution and easy to penetrate the blood-brain barrier, and the advantages of toxicological safety, stable metabolism, long half-life period and small side effects are achieved.

The invention relates to a preparation method and application of an exendin analog having undergone site-directed modification by a polyethylene glycol derivative. A product obtained after specific modification of the C terminal of the exendin analog by polyethylene glycol has biological activity similar to the biological activity of exendin-4 and has longer half life in vivo compared with unmodified exendin-4. The polyethylene glycol-modified exendin analog disclosed in the invention is applied to treatment diabetes type II and myocardial infarction and has the advantages of simple preparation, obvious curative effect, long-acting and stable drug effect, easiness in storage, etc. The polyethylene glycol-modified exendin analog is of great significance to promotion of high-efficiency treatment of and development of novel drugs for diabetes and myocardial infarction.

The invention discloses a PEG modified polymyxin or medicinal salt shown in the formula I and a preparation method and application of the PEG modified polymyxin or medicinal salt. The PEG modified polymyxin is a stable compound formed by connecting PEG molecules to polymyxin through covalent bonds. The molecular weight of the PEG modified polymyxin is multiplied, the half-life period is prolonged, and the aims of enhancing the treatment effect and reducing toxicity are achieved. Please see the molecular formula I in the description.

The invention discloses a raw maltogenic amylase production bacterial strain and belongs to the technical field of genetic engineering. According to the raw maltogenic amylase production bacterial strain disclosed by the invention, raw maltogenic amylase for preparing maltose is constructed at first, the maltose content of the maltogenic amylase can be improved to 96% or above when a conversion reaction is performed for 10 h, the contents of trisaccharide and tetrasccharide is close to 0 when the reaction is performed for 5 h, and the characteristics of low byproducts, high catalytic efficiency and the like can be achieved. By means of self-assembly oligopeptide modification, mutant temperature stability is remarkably improved, a half-life period is prolonged to 304 h from 97 h, and the optimum temperature is more suitable for a temperature required by a saccharifying process. The raw maltogenic amylase production bacterial strain disclosed by the invention successfully realizes heterogeneous expression of the maltogenic amylase, is favorable for the large-scale preparation of the raw maltogenic amylase suitable for producing maltose.

The invention discloses a novel derivative of 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol and application of the novel derivative. The novel derivative has good medicine activity, can greatly prolong the half-life period of a medicine, prolongs the retention time of the medicine in a human body, and meanwhile, improves the concentration of the medicine in blood; therefore, a better curative effect is achieved. As the half-life period of the medicine is greatly prolonged, the activity concentration of the medicine in the blood can be maintained for a longer period of time; under the cure condition of dose constrain, the curative effect is maintained and the dosage of the medicine is reduced, so that the problem of bad metabolism of the medicine is eliminated, the medicine toxicity is reduced, and the toxic and side effects in the medicine use process are reduced.